Anzeige
+++0,01 % von 1 BILLIONEN USD = 100 MILLIONEN USD - Und UberDoc ist gerade erst an die Börse gegangen+++
Original-Research

Cantourage Group SE (von NuWays AG): BUY 18.03.2026, 09:00 Uhr von EQS Research Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Cantourage Group 4,715 EUR -0,11 % Lang & Schwarz

Original-Research: Cantourage Group SE - from NuWays AG

18.03.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to Cantourage Group SE

Company Name: Cantourage Group SE
ISIN: DE000A3DSV01
 
Reason for the research: Update
Recommendation: BUY
Target price: EUR 10
Target price on sight of: 12 months
Last rating change:
Analyst: Christian Sandherr

FY25 prelim confirm the growth story; chg. est.

Cantourage published preliminary group figures for FY25, reporting sales of € 92.8m (eNuW old: € 88.6m), implying growth of 82% yoy vs. € 50.9m in FY24. Preliminary EBITDA rose to € 5.7m, largely in line with our expectations of € 6m. Most importantly, the preliminary results confirm the operational momentum cross the group’s end markets. This is despite the temporary pricing headwinds in Germany in H2 as the group evidently compensated through volume, an increasing focus on less effected premium strains and strongly growing sales in the UK and Poland.

International expansion gaining traction. The company’s focused rollout across key European markets is increasingly supporting both top-line growth and overall earnings quality. The UK alone contributed more than 20% of total group revenue in 2025. This is relevant for two main reasons: firstly, UK sales are structurally higher-margin (higher avg. selling price compared to Germany’s more volume-driven flower segment; secondly, a broader geographic footprint helps alleviate regulatory concentration risk, which has historically weighed on market sentiment.

In addition to the UK, Poland is also expanding at a pace well above the underlying market. Consistent with its strategy, further entries into European markets are likely over the short to medium term (eNuW), reinforcing the company’s transition into a pan-European player.

Greater emphasis on premiumisation in Germany. Profitability in the German market has come under pressure due to intensified price competition in the lower-end segment, following a surge in supply, partly triggered by regulatory uncertainty and subsequent inventory adjustments across the industry, particularly over the summer period. In response, Cantourage has repositioned its portfolio towards higher-margin premium strains, which tend to be more resilient to demand volatility. As a result, competitive differentiation is shifting away from scale towards product curation and quality.

FY26e sales to exceed € 100m (8% yoy growth, eNuW) despite the challenging market conditions in Germany as Cantourage is successfully repositioning the local product portfolio and international markets retain high growth rates. More importantly, margins are seen to further improve to 8.5% (EBITDA), +2.4pp yoy, benefitting from the aforementioned premiumisation in Germany and a strategic shift (opportunistically) from pass-through distributor to principal buyer, taking inventory onto its own book and capturing a structurally larger share of the margin stack.

Valuation remains deeply undemanding. The prelims reinforce the M&A reference point we established in our last note. The Sanity/Organigram transaction at ~4.2x EV/sales for a wholesale-only, barely profitable business stands in stark contrast to Cantourage's ~0.7x EV/Sales FY25p with a clearly positive and growing EBITDA. The market continues to under-price both the operational trajectory and the de-risking of the regulatory overhang. We confirm our BUY rating with an unchanged € 10 PT (DCF-based).
 

You can download the research here: cantourage-group-se-2026-03-18-previewreview-en-d2e6f
For additional information visit our website: https://www.nuways-ag.com/research-feed

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2293230  18.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer